Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.
Mazzola, R.D., Zhu, Z., Sinning, L., McKittrick, B., Lavey, B., Spitler, J., Kozlowski, J., Neng-Yang, S., Zhou, G., Guo, Z., Orth, P., Madison, V., Sun, J., Lundell, D., Niu, X.(2008) Bioorg Med Chem Lett 18: 5809-5814
- PubMed: 18835710 
- DOI: https://doi.org/10.1016/j.bmcl.2008.09.045
- Primary Citation of Related Structures:  
3E8R, 3EDZ - PubMed Abstract: 
A series of cyclopropyl hydroxamic acids were prepared. Many of the compounds displayed picomolar affinity for the TACE enzyme while maintaining good to excellent selectivity profiles versus MMP-1, -2, -3, -7, -14, and ADAM-10. X-ray analysis of an inhibitor in the TACE active site indicated that the molecules bound to the enzyme in the S1'-S3' pocket.
Organizational Affiliation: 
Department of Medicinal Chemistry, Schering Plough Research Institute, Kenilworth, NJ 07033, USA. robert.mazzola@spcorp.com